# US 2013/0274266 A1 · 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0274266 A1
- Document ID: US20130274266A1
- Status: Published application
- Kind: A1
- Application number: 13/995,523
- Filed: 2011-12-21
- Published: 2013-10-17
- Earliest claimed: 2011-12-21
- Assignees: Janssen Pharmaceutica NV
- Inventors: Andres Avelino Trabanco-Suárez; Francisca Delgado-Jiménez; Juan Antonio Vega Ramiro; Gary John Tresadern; Henricus Jacobus Maria Gijsen; Daniel Oehlrich
- Web page: https://patentgrep.com/patent/US20130274266A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to novel 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, cerebrovascular amyloid angiopathy, multi-infarct dementia, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease or dementia associated with beta-amyloid.

## Claims

### Claim 1

A compound of Formula (I)
or a tautomer or a stereoisomeric form thereof, wherein
R1 and R2 are independently selected from the group consisting of hydrogen, halo, cyano, C1-3alkyl, mono- and polyhalo-C1-3alkyl, and C3-6cycloalkyl;
R3 is selected from the group consisting of hydrogen, C1-3alkyl, C3-6cycloalkyl, mono- and polyhalo-C1-3alkyl, homoaryl and heteroaryl;
X1, X2, X3, X4 are independently C(R4) or N, provided that no more than two thereof represent N; each R4 is selected from the group consisting of hydrogen, halo, C1-3alkyl, mono- and polyhalo-C1-3alkyl, cyano, C1-3alkyloxy, mono- and polyhalo-C1-3alkyloxy;
L is a bond or —N(R5)CO—, wherein R5 is hydrogen or C1-3alkyl;
Ar is homoaryl or heteroaryl;
wherein homoaryl is phenyl or phenyl substituted with one, two or three substituents selected from the group consisting of halo, cyano, C1-3alkyl, C1-3alkyloxy, mono- and polyhalo-C1-3alkyl;
heteroaryl is selected from the group consisting of pyridyl, pyrimidyl, pyrazyl, pyridazyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, and oxadiazolyl, each optionally substituted with one, two or three substituents selected from the group consisting of halo, cyano, C1-3alkyl, C1-3alkyloxy, mono- and polyhalo-C1-3alkyl; or
an addition salt or a solvate thereof.

### Claim 2 (depends on 1)

The compound of claim 1 wherein,
R1 and R2 are independently selected from the group consisting of hydrogen, mono-, di- and trifluoromethyl, chloro, bromo and cyano;
R3 is C1-3alkyl or mono-, di- and trifluoromethyl;
X1 and X3 are independently CH or CF; X2 and X4 are CH;
L is —N(R5)CO—, wherein R5 is hydrogen;
Ar is homoaryl or heteroaryl;
wherein homoaryl is phenyl substituted with one or two substituents selected from the group consisting of halo, cyano, C1-3alkyl, and C1-3alkyloxy;
heteroaryl is selected from the group consisting of pyridyl, pyrimidyl, pyridazyl, pyrazolyl, oxazolyl and isothiazolyl, each optionally substituted with one or two substituents selected from the group consisting of halo, cyano, C1-3alkyl, C1-3alkyl-oxy, mono-, di- and trifluoromethyl; or
an addition salt or a solvate thereof.

### Claim 3 (depends on 1)

The compound of claim 1 wherein,
R1 is hydrogen, mono-, di-, or trifluoromethyl, chloro, bromo or cyano;
R2 is hydrogen, chloro, cyano, mono-, di- or trifluoromethyl;
R3 is methyl, mono- di-, or trifluoromethyl;
X1 is CF; X2, X3, X4 are CH;
L is —N(R5)CO—, wherein R5 is hydrogen;
Ar is heteroaryl;
wherein heteroaryl is selected from the group consisting of pyridyl, pyrazyl and pyrazolyl, each substituted with one or two substituents selected from the group consisting of chloro, fluoro, cyano, methyl, methoxy, ethoxy, mono-, di-, and trifluoromethyl; or
an addition salt or a solvate thereof.

### Claim 4 (depends on 1)

The compound of claim 1 wherein the carbon atom substituted with R3 has the R-configuration.

### Claim 5 (depends on 1, 2, 3, 4)

A pharmaceutical composition comprising a therapeutically effective amount of a compound as defined in any one of claims 1 to 4 and a pharmaceutically acceptable carrier.

### Claim 6 (depends on 1, 2, 3, 4, 5)

A process for preparing a pharmaceutical composition as defined in claim 5, characterized in that a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a compound as defined in any one of claims 1 to 4.

### Claim 7 (depends on 1, 2, 3, 4)

A compound as defined in any one of claims 1 to 4 for use in the treatment or prevention of Alzheimer's disease, mild cognitive impairment, senility, dementia, dementia with Lewy bodies, cerebral amyloid angiopathy, multi-infarct dementia, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease or dementia associated with beta-amyloid.

### Claim 8 (depends on 1, 2, 3, 4, 5)

A method of treating a disorder selected from the group consisting of Alzheimer's disease, mild cognitive impairment, senility, dementia, dementia with Lewy bodies, cerebral amyloid angiopathy, multi-infarct dementia, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease and dementia associated with beta-amyloid, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound as defined in any one of claims 1 to 4 or a pharmaceutical composition as defined in claim 5.
